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Abstract
Background: LGR6 (leucine-rich repeat containing, G protein-coupled receptor 6) is a member of the rhodopsin-like seven
transmembrane domain receptor superfamily with the highest homology to LGR4 and LGR5. LGR6 was found as one of the
novel genes mutated in colon cancer through total exon sequencing and its promoter region is hypermethylated in 20–50%
of colon cancer cases. In the skin, LGR6 marks a population of stem cells that can give rise to all cell lineages. Recently, we
and others demonstrated that LGR4 and LGR5 function as receptors of R-spondins to potentiate Wnt/b-catenin signaling.
However, the binding affinity and functional response of LGR6 to R-spondins, and the activity of colon cancer mutants of
LGR6 have not been determined.
Principal Findings: We found that LGR6 also binds and responds to R-spondins 1–3 with high affinity to enhance Wnt/b-
catenin signaling through increased LRP6 phosphorylation. Similar to LGR4 and LGR5, LGR6 is not coupled to heterotrimeric
G proteins or to b-arrestin following R-spondin stimulation. Functional and expression analysis of three somatic mutations
identified in colon cancer samples indicates that one mutant fails to bind and respond to R-spondin (loss-of-function), but
the other two have no significant effect on receptor function. Overexpression of wild-type LGR6 in HeLa cells leads to
increased cell migration following co-treatment with R-spondin1 and Wnt3a when compared to vector control cells or cells
overexpressing the loss-of-function mutant.
Conclusions: LGR6 is a high affinity receptor for R-spondins 1–3 and potentially functions as a tumor suppressor despite its
positive effect on Wnt/b-catenin signaling.
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Introduction
LGR6 (leucine rich-repeat containing, G protein-coupled
receptor 6) is a member of the glycoprotein hormone receptor
subfamily of rhodopsin-like, seven transmembrane domain (7TM)
receptors [1]. It is most homologous to two other receptors, LGR4
and LGR5 with 50% identity between each other at the amino
acid level [1]. The trio of receptors (LGR4–6) is unique in having a
large N-terminal extracellular domain (ECD) containing 17
leucine-rich repeats which are flanked by cysteine-rich sequences
at both the N- and C-termini. Another common feature of the
three receptors is their expression in distinct types of adult stem
cells [2]. LGR6 was shown to mark a group of stem cells in the
skin that can give rise to all cell lineages of the skin, including those
of the hair follicle, sebaceous gland, and interfollicular dermis [3].
LGR5 marks a distinct population of stem cells in the skin, which,
however, only provide progenitor cells of hair follicles [4]. In the
gastrointestinal tract, LGR5 marks the rapidly cycling stem cells in
the crypts that can give rise to all cell types of the gut epithelium
[5]. LGR4, though not a marker of adult stem cells, is generally
expressed at high levels in proliferating cells of many tissues,
including adult stem cells and early progenitors cells [2,6,7].
Importantly, LGR4 is essential for the survival and proliferation of
the crypt stem cells [7,8]. These observations suggest that LGR4–6
have unique ligands and signaling mechanisms as they are the only
receptors, among hundreds of members of the rhodopsin family,
found to be specifically expressed in adult stem cells and/or
essential for their survival.
Recently, we and others demonstrated that LGR4 and LGR5
function as receptors of the R-spondin family of stem cell factors to
potentiate Wnt/b-catenin signaling [8–10]. R-spondins (RSPOs)
are a group of four secreted proteins (RSPO1–4) that share an
overall identity of 40–60% at the amino acid sequence level and
are comprised of similar domains [11]. They were originally
identified as Wnt agonists based on their robust, positive effect on
Wnt/b-catenin signaling [12,13]. Stimulation of LGR4 or LGR5
with any of the four RSPOs greatly potentiates b-catenin-
dependent transcription induced by Wnt3a, with RSPO2 and
RSPO3 showing the highest potency and affinity [9]. Though
LGR4 and LGR5 contain a 7TM domain with significant
homology to those of the rhodopsin family of GPCRs, and are
predicted to be G protein-coupled receptors, stimulation of neither
receptor with RSPOs lead to changes in intracellular levels of
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2+, or translocation of b-arrestin [9]. Wnt/b-catenin
signaling, also referred to as canonical Wnt signaling, is initiated
through phosphorylation of the Wnt coreceptors LRP5/6 at
multiple sites following Wnt ligand stimulation [14,15]. One of the
key phosphorylation sites is Ser-1490 of LRP6, which is greatly
enhanced by co-treatment with RSPO [9,16]. Therefore, activa-
tion of LGR4/5 by RSPOs most likely leads to increased activity
of one or multiple kinases that phosphorylate LRP6 through a yet
unknown mechanism.
LGR6 was shown to be able to rescue the effect of R-spondin on
Wnt/b-catenin signaling in HEK293T cells when endogenously
expressed LGR4 was knocked down [8], suggesting that LGR6
functions similarly as LGR4 and LGR5. However, activation of
LGR6 by the different RSPOs has not yet been characterized.
More importantly, LGR6 was found to be one of the commonly
mutated genes in a group of colon cancer samples that were
sequenced by whole-exon sequencing [17]. Out of 37 colon cancer
samples randomly selected for sequencing, three mutations (299–
300insGRS, G725C, and P928H) in LGR6 were found, with the
mutation P928H being homozygous [17]. An independent,
transcriptome-wide approach also found that the promoter region
of LGR6 is hypermethylated in ,20% of colon cancer cases [18].
A follow-up analysis showed that LGR6 is hypermethylated in
,50% of colon cancer [19,20], suggesting that LGR6 functions as
a tumor suppressor. We mined the COSMIC (Catalogue Of
Somatic Mutations In Cancer [21]) database for additional
mutations and found that LGR6 is also somatically mutated in
cancers of the ovary and pancreas [21]. The Wnt/b-catenin
signaling pathway is well known to have critical roles in the
initiation and growth of many types of cancer, especially in colon
cancer, as nearly 90% of colon cancers have aberrant activation of
this pathway [22]. Therefore, it is important to determine if LGR6
interacts with the different RSPOS to regulate Wnt/b-catenin
signaling and whether the cancer mutations affect LGR6-
mediated signaling. In this study, we have characterized the
binding and activation of LGR6 by RSPOs. To gain a better
understanding of the function of LGR6 in Wnt/b-catenin
signaling and oncogenesis, we also evaluated the activity of the
different LGR6 mutants identified in colon cancer. Here we show
that one of the mutants is incapable of binding to R-spondins and
fails to activate Wnt/b-catenin signaling.
Results
R-Spondin binds to and co-internalizes with LGR6
Previously, we reported that R-spondins bind to and co-
internalize with LGR4 and LGR5 using immunofluoresence and
whole cell binding analysis [9]. We used the same methods to
examine if they can also bind to and co-internalize with LGR6.
HEK293 cells stably expressing human LGR6 with a Flag-tag at
the N-terminus were generated and used in the binding study. A
fusion protein consisting of mouse RSPO1 with mouse IgG2a-Fc
at the C-terminus (designated mRSPO1-Fc) was shown to be
biologically active [23] and used here as a probe. When mRSPO1-
Fc was incubated with live cells expressing LGR6 at 4uCt o
prevent internalization, a strong signal was detected using an anti-
IgG2a antibody (Fig. 1A, upper mid panel) while no signal was
observed in the absence of mRSPO1-Fc (Fig. 1A, lower mid
panel). Co-staining with an anti-Flag antibody showed strong
receptor expression in both cases (Fig. 1A, upper and lower left
panels). No binding of mRSPO1-Fc to vector control cells could be
detected [9]. When the binding was performed at 37uC with live
cells, both LGR6 (red) and mRSPO1-Fc (green) were observed in
intracellular bodies (Fig. 1B, upper left and mid panels), indicating
that both mRSPO1-Fc and LGR6 were internalized. Superim-
posing of the two images revealed near 100% co-localization of
mRSPO1-Fc with LGR6 (Fig. 1B, upper right panel). Again, no
anti-IgG2a signal was detected in the absence of mRSPO1-Fc
(Fig. 1B, lower mid panel), or in vector control cells [9]. It should
be mentioned that intracellular staining of LGR6 was also
observed in the absence of mRSPO1-Fc (Fig. 1B, lower left
panel), suggesting that a significant portion of LGR6 was
internalized by either constitutive activity or endogenous expres-
sion of RSPOs in HEK293 cells [9,12,24]. We then used
competition binding analysis to determine the affinities of the
four RSPOs in binding to LGR6. As shown in Figure 1C, all
RSPOs are able to displace the binding of mRSPO1-Fc
completely. The IC50s displayed by RSPO1, 2, 3, and 4 under
these conditions are 3.3, 0.5, 1.7, and 7 nM, respectively. Taken
together, these results show that RSPO1–4 bind to LGR6 strongly
and specifically, with RSPO2 showing the highest affinity.
Furthermore, the affinity profile of LGR6 for RSPO1–4 is highly
similar to that of LGR5 [9].
Stimulation of LGR6 with RSPO1–3 enhances Wnt/b-
catenin signaling and this activity is inhibited by Dkk1
Since RSPOSs are well known to enhance b-catenin signaling in
a Wnt-dependent manner [12,13,16,25,26], we next investigated
whether LGR6 can affect the activity of RSPO in this pathway.
Activation of Wnt/b-catenin signaling is routinely measured by
monitoring the activity of the Super TOPflash construct which
contains a reporter enzyme under the control of 8 TCF/LEF b-
catenin-responsive elements [27,28]. Using the Super TOPflash
assay, we examined the effect of R-spondin treatment on Wnt
signaling in HEK293T cells overexpressing LGR6 in the presence
of low concentrations of exogenous Wnt3a which is required for
R-spondin to function [25]. Overexpression of LGR6 increased
the potency of RSPO1 by ,30-fold when compared to vector-
transfected cells (Fig. 2A). For RSPO2, strong, endogenous
response was observed in vector cells, which was further enhanced
upon transfection of LGR6 as shown by the increased potency of
the ligand (Fig. 2A). A similar increase in potency was also found
for RSPO3 (Fig. 2B). On the other hand, overexpression of LGR6
had no effect on the activity of RSPO4 even though RSPO4
showed high affinity binding to LGR6 (Fig. 1C and Fig. 2B).
Previously, it was demonstrated the endogenous response to
RSPOs in HEK293T cells are predominantly mediated by LGR4
[8–10]. Overexpression of LGR4 or LGR5 in these cells still led to
dramatic increase in the potencies of RSPO1–4 (,1000-fold in the
case of RSPO2) [9]. LGR6 binds RSPO1–4 with affinities similar
to those of LGR5, but showed much less dramatic effect on the
potencies of the four ligands in the Wnt/b-catenin signaling assay.
These results suggest that LGR6 is intrinsically weaker in
potentiating Wnt/b-catenin signaling following RSPO stimula-
tion. Alternatively, RSPO binding to LGR6 may lead to activation
of other signaling pathways yet to be identified.
Dickkopf 1 (Dkk1) antagonizes canonical Wnt signaling by
competitively binding to the Wnt ligand binding site of LRP6.
This prevents the activity of RSPOs, since co-stimulation with a
Wnt ligand is required for RSPOs [24,29–34]. We then tested the
effect of Dkk1 on the LGR6-mediated increase in the activity of
RSPO1, since the RSPO1 ligand exhibited the weakest endoge-
nous response in HEK293T cells (Fig. 2A). Cotransfection of Dkk1
completely blocked RSPO1 signaling in vector cells as well as in
LGR6-transfected cells (Fig. 2C), similar to what was observed
with LGR4 and LGR5 [9]. These data suggest that LGR6
functions in a similar mechanism to that of LGR4/5 in mediating
RSPO-induced potentiation of Wnt/b-catenin signaling.
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arrestin following RSPO stimulation
Since LGR4–6 contain a 7TM domain typical of rhodopsin-like
GPCRs, they are thus predicted to be coupled to heterotrimeric G
proteins for signal transduction [1]. Heterotrimeric G proteins are
classified into four groups, Gas(stimulation of cAMP production),
Figure 1. Binding of R-spondins to LGR6 by confocal immuno-
fluorescence analysis and competition binding assay. A&B,
HEK293 cells stably expressing Flag-LGR6 were incubated with
mRSPO1-Fc or control conditioned media (CM) at 4uC (A), or at 37uC
(B). Flag-LGR6 was detected with a Cy3-labeled anti-Flag antibody (red)
and mRSPO1-Fc was detected using Alexa488-labeled anti-IgG2a
antibody (green). Nuclei were counterstained with To-Pro-3 (blue).
The data shown are from one of three independent experiments with
similar results. C, Quantitative binding analysis using a whole-cell-based
assay. HEK293 cells stably expressing Flag-LGR6 were incubated with
mRSPO1-Fc plus serial dilutions of purified recombinant RSPO1–4.
Maximum specific binding is defined by the difference between the
data with and without mRSPO1-Fc, which is ,50% of total binding in
general. All error bars are SEM (n=3).
doi:10.1371/journal.pone.0037137.g001
Figure 2. LGR6 enhances Wnt/b-catenin signaling in response
to RSPO1–3 and this activity is inhibited by Dkk1. HEK293T cells
were transiently transfected with LGR6 or vector control, plus Dkk1
expression plasmids as indicated, along with the b-catenin reporter
plasmid super 86 TOPFlash (firefly luciferase) and pRL-SV40 (renilla
luciferase) and then stimulated with serial dilutions of purified
recombinant RSPO1–2 (A), RSPO3–4 (B) or RSPO1 (C) in the presence
of Wnt3a CM. Firefly luciferase activity of each well was normalized to
that of renilla luciferase activity of the same well. All error bars are SEM
(n=4).
doi:10.1371/journal.pone.0037137.g002
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2+ mobiliza-
tion), and Ga(12/13) (Rho activation) [35]. In addition, nearly 90%
of GPCRs induce b-arrestin translocation for receptor desensiti-
zation and alternative signaling [36]. Previously, we demonstrated
that stimulation of LGR4 or LGR5 with RSPOs did not induce
changes in any of the pathways typically associated with GPCR
activation, i.e., cAMP alteration, Ca
2+ mobilization, or b-arrestin
translocation [9]. We therefore investigated if this is also true for
LGR6. First, we examined cAMP response in cells transiently
transfected with vector control or LGR6 after treatment with
various concentrations of RSPO1–2. No hint of increased cAMP
production in either control or LGR6 cells was observed (Fig. 3A).
As a positive control, these cells showed a normal, robust increase
in cAMP levels in response to forskolin stimulation (Fig. 3B). We
then tested if LGR6 inhibits forskolin-stimulated cAMP produc-
tion, but found no such activity at any of the tested concentrations
of RSPO1 or RSPO2 (Fig. 3C). Analysis of Ca
2+ mobilization also
failed to detect any LGR6-mediated activity (Fig. 3D). We also
examined if activation of LGR6 is coupled to the Ga(12/13)
pathway using a serum response factor-based reporter enzyme
assay, which is one of the standard methods for monitoring
activation of this pathway [37]. Cells transfected with either vector
control or LGR6 showed no response to RSPO1 in this assay, with
or without Wnt3a co-treatment (Fig. 3E). Treatment with fetal
bovine serum (FBS), as expected, resulted in a dose-dependent
increase in reporter enzyme activity (Fig. 3F). LGR6-transfected
cells showed a moderate increase in the potency of serum, the
significance of which needs further investigation. Lastly, we
investigated if b-arrestin is involved in LGR6 activation. No
translocation of b-arrestin was detected in HEK293T cells
transfected with vector or LGR6 following treatment with RSPO1
(Fig. 3G). LGR6 expression and ligand-receptor co-localization
were clearly confirmed (Fig. 3G). As positive control, cells
expressing b2-adrenerigc receptor showed robust translocation of
b-arrestin following stimulation with its agonist (Fig. 3H).
Furthermore, co-stimulation with recombinant Wnt3a in any of
the above GPCR assays made no difference. Taken together, these
data indicate that LGR6, like LGR4 and LGR5, is not coupled to
any of the heterotrimeric G protein classes or to b-arrestin, at least
when stimulated by RSPOs.
LGR6 mutation identified in colon cancer has loss of
function
Total exon or complete genomic sequencing has increasingly
been used to identify all mutations of cancer genomes in a
nonbiased fashion [17,38]. In the very first sequencing of total
exons from breast and colon cancer samples, LGR6 was found to
be one of the commonly mutated genes in colon cancer with three
mutations found in a total of 37 cases [17]. Two of the three
mutations are missense and the 3
rd one was an inframe insertion of
three amino acid residues (Table 1) [17]. Since then, one
additional mutation was found in pancreatic cancer and two in
ovarian cancer (Table 1) [21,39]. However, the consequences of
these mutations, with one exception, have never been determined
since no functional assay was available until now. The frameshift
mutation (230fs*6) found in ovarian cancer truncates 737 out of
967 amino acids and is thus expected to be a loss-of-function
mutation. With the finding that LGR6 functions as a receptor of
RSPOs to potentiate Wnt/b-catenin signaling, we set out to
determine the activity of the three mutants identified in colon
cancer by comparing them with LGR6 WT. The three mutants
and LGR6 WT, along with vector control, were transfected into
HEK293T cells and their responses to RSPO1 were compared
side-by-side. The two point mutation mutants, G725C and
P928H, showed increased responses that are not significantly
different from WT (Fig. 4A), implying that they do not affect
RSPO1-simulated LGR6 activity. The response curve of the
insGRS mutant, however, was indistinguishable from that of
vector control (Fig. 4A), suggesting that it has lost the function of
responding to RSPO1 in potentiating Wnt/b-catenin signaling.
Immunoblot analysis showed all receptors were expressed at a
similar level (Fig. 4B), indicating no defects in expression.
Next, we investigated potential defects of the insGRS mutant by
comparing its activities with those of WT with respect to LRP6
phosphorylation, accumulation of non-membranous b-catenin,
and ligand binding. HEK293T cells were transiently transfected
with vector control, LGR6WT, or insGRS plasmids and treated
with RSPO1 for different periods of time (0 to 6 hrs) before being
harvested for analysis. In vector control cells, RSPO1 stimulation
increased LRP6 phorphorylation and accumulation of b-catenin
as expected (Fig. 4C). In LGR6 transfected cells, phosphorylation
was further increased across all time points (Fig. 4C), consistent
with the increased activity in the Super TOPflash reporter enzyme
assay. In LGR6-insGRS-transfected cells, both LRP6 phosphor-
ylation and b-catenin accumulation were reduced at later time
points when compared to vector control cells (Fig. 4C), indicating
the mutant is defective in enhancing Wnt3a-stimulated signaling.
Again, the expression level of the mutant was similar to that of the
WT receptor based on western blot analysis (Fig. 4C). We then
performed ligand binding analysis to determine if the LGR6-
insGRS receptor is still capable of binding to RSPO1, especially
since the mutation is located in the presumed ligand-binding ECD.
When the binding was carried out at 37uC, LGR6-insGRS-
expressing cells showed receptor staining at both the cell surface
and in the cytoplasmic space (Fig. 4D, upper left panels). However,
no staining of mRSPO-Fc was observed, indicating that the
mutant is incapable of binding to the ligand. LGR6-WT-
expressing cells showed strong staining of the ligand which is co-
localized with the receptor (Fig. 4D, lower panels). Furthermore,
examination of the intracellular staining pattern of the insGRS
mutant found no vesicular structures typically observed with
LGR4–6 (Fig. 4A, left panels) [9]. This suggests that the mutant
does not undergo normal receptor internalization, potentially due
to its failure to bind ligand. The strong, non-vesicular intracellular
staining also suggests that the mutant is potentially defective in
trafficking to the membrane after synthesis in the ER. Collectively,
these data indicate that RSPO1 stimulation of LGR6-WT
enhanced Wnt-induced LRP6 phosphorylation and b-catenin
accumulation, leading to increased Wnt signaling output. Of the
three mutants found in colon cancer through random sequencing,
only the insGRS mutant has loss of function. This loss of function
is due to its inability to bind ligand, which may be attributed to a
conformational change in the receptor as a consequence of the
insertion of three amino acid residues in the ECD’s leucine-rich
repeat #10. Together with the finding that LGR6 is hypermethy-
lated in up to 50% of colon cancer samples and an LGR6
truncation mutant has been identified in ovarian cancer, these
data imply that LGR6 functions as tumor suppressor for colon and
ovarian cancer.
Overexpression of LGR6 increases cell migration
To understand potential roles and mechanisms of LGR6 in
oncogenesis, we profiled a panel of colon cancer and uterine
cancer cell lines for expression levels of LGR4–6 and RSPO1–4
(Fig. 5A–B). Of the three receptors, LGR4 is the most commonly
and abundantly expressed receptor in the cancer cell lines, with
the exception of the HCT116 cells (Fig. 5A). LGR6 is expressed at
negligible levels except in Colo320 cells. Interestingly, none of the
LGR6 Ligands and Its Role in Cancer
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previous published results showed HeLa cells express high levels of
RSPO3 [12] (Fig. 5B). To examine the effect of LGR6 on growth
and migration of cancer cells, we attempted to overexpress LGR6
WT and insGRS mutant in SW620 cells which have relative low
expression of LGR4–6 and are routinely used as a model of colon
cancer studies. However, repeated efforts failed to establish cell
lines stably expressing WT or mutant LGR6. We then used HeLa
cells as a host cell line and obtained bulk cell lines stably expressing
FLAG-tagged LGR6 WT or insGRS after sorting with anti-Flag
antibody (Fig. 5 D–E). No difference among the three cell lines
expressing vector, LGR6-WT or LGR6-insGRS was observed in
growth rate as measured by the xCelligence assay (data not
shown). We then compared migration of the three cell lines treated
with vehicle control, RSPO1, Wnt3a, or Wnt3a+RSPO1. No
significant difference in baseline migration was observed among
the three cell lines (Fig. 5C). Interestingly, cells expressing LGR6-
WT displayed increased migration when treated with
Figure 3. LGR6 is not coupled to heterotrimeric G proteins or to b-arrestin following R-spondin stimulation. A, No cAMP response was
detected in vector and LGR6 cells treated with RSPO1–2. B, Forksolin showed a strong stimulation of cAMP production in both cells. C, RSPO1–2
treatments had no effect on forskolin-stimulated cAMP production in vector and LGR6 cells. D, No Ca
2+ mobilization was induced in vector and LGR6
cells in response to RSPO1, whereas ATP gave a robust response in both cells. E, Stimulation of LGR6 and vector cells by RSPO1 had no effect in the
Ga(12/13) pathway using the serum response factor reporter enzyme assay. F, FBS gave a dose-dependent response in the serum response factor
reporter enzyme assay. G, No translocation of b-arrestin was observed in LGR6 cells treated with mRSPO1-Fc, whereas colocalization of mRSPO1-Fc
with LGR6 was confirmed. H, Robust translocation of b-arrestin was observed in HEK293 cells transfected with b2-adrenergic receptors and stimulated
with its agonist isoproterenol.
doi:10.1371/journal.pone.0037137.g003
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the vector control showed no response, confirming the loss of
function result for the insGRS mutant. Confocal immunofluore-
sence analysis showed that the insGRS mutant, like in HEK293
cells, is not located in intracellular bodies (Fig. 5D). In contrast,
WT LGR6 consistently displayed a pattern of vesicular staining
(Fig. 5D). These results indicate that overexpression of LGR6 in
HeLa cells can increase cell migration when co-stimulated by
Wnt3a and RSPO1.
Discussion
In the present study we determined the affinity and potency of
LGR6 for RSPO1–4 in potentiating Wnt/b-catenin signaling, and
characterized the activity of three mutations identified in colon
cancer samples. Compared to LGR4 and LGR5, LGR6
appears to have a more limited tissue distribution with lower
expression in general (http://www.ncbi.nlm.nih.gov/UniGene/
ESTProfileViewer.cgi?uglist=Hs.497402). Knockout of LGR6 in
the mouse has no obvious phenotype while homozygous deletion
of either LGR4 or LGR5 leads to total embryonic or neonatal
lethality [3,40,41]. As loss of RSPOs leads to embryonic lethality
or major developmental defects [42], these observations suggest
that LGR6 does not have a major role in mediating the effect in
RSPOs in vivo. Interestingly, our in vitro analysis substantiates
that LGR6 is much less effective in potentiating RSPO-mediated
Wnt/b-catenin signaling as shown by the much less dramatic
increase in the potencies of RSPO1–4 when compared to LGR4/
5, even though recombinant expression of LGR6 gave comparable
receptor levels and binding affinities for RSPO1–4. Assuming the
7TM domain of LGR4–6 is responsible for receptor signaling, we
compared the 7TM sequence of LGR6 with those of LGR4 and
LGR5, and found that LGR6 is unique in one potentially
important motif. The ‘‘DRY’’ motif located at the end of TM3, of
which the Arg residue (often referred to as residue 3:50) is almost
absolutely conserved in the rhodopsin family of GPCRs. In LGR4
and LGR5, the sequence is ‘‘ERG’’ and ‘‘ERS’’, respectively. In
LGR6, however, the sequence is ‘‘QCS’’, representing one of the
rare cases of receptors without an Arg residue at the 3:50 position
in the rhodopsin family. This deviation may be one of the factors
for the decreased efficacy of LGR6 in potentiating Wnt/b-catenin
signaling.
Similar to LGR4 and LGR5, LGR6 is not coupled to
heterotrimeric G proteins or to b-arrestin following stimulation
with RSPO alone or RSPO plus Wnt3a. This conclusion is based
on our analysis of 2
nd messengers, Ga(12/13)-induced transcrip-
tional activation, and b-arrestin translocation. The observation
that HEK293T cells showed no hint of endogenous response to
RSPO1 or SPO2 in the Ga(12/13) assay also indicates that LGR4 is
not coupled to this pathway since these cells have strong
endogenous expression of LGR4 and respond to RSPO1
stimulation in the Wnt/b-catenin signaling assay [8,9]. Though
the 7TM region of LGR4–6 has significant overall homology to
those of rhodopsin-like GPCRs and contains all the important
motifs, it does have unique features that may hold the answer to
their lack of coupling to G proteins. The intracellular loop
between TM5 and TM6 in GPCRs directly interacts with the a
subunit of the heterotrimeric complex [43], and generally has an
overall basicity (pI=,9). For LGR4–6, however, the loops have a
calculated pI of ,5.5, which can potentially hinder interactions
with G proteins. The CWXP motif in TM6, commonly conserved
in the rhodopsin family of receptors, has the sequence XXCP for
LGR4–6. This motif plays a critical role in the activation of
heterotrimeric G proteins [35,44,45]. All the other members of the
LGR family (LGR1–3 and LGR7–8), which are universally
coupled to Gas and are the most closely related homologs of
LGR4–6, have the sequence CMAP (LGR1–3) or CWIP (LGR7–
8) for this motif [46]. The Drosophila receptor dLGR2, a Gas-
coupled receptor for the neuropeptide bursicon [47,48], is most
homologous to LGR4–6 and was believed to be the invertebrate
ortholog of mammalian LGR4–6 [49]. Notably, dLGR2 has the
sequence CWSP for this motif. Interestingly, orthologs of RSPOs
have not been identified in invertebrates and bursicon-like
mammalian peptides such as gremlins don’t not activate LGR4–
6 [9]. Therefore, we speculate that LGR4–6 have evolved away
from their typical ancestor GPCRs to function as receptors for the
newly evolved RSPO proteins to potentiate Wnt/b-catenin
signaling in vertebrates. In fact, several regulators of the Wnt
signaling pathways are only found in vertebrates, such as DKK1
and WTX, both of which inhibit canonical Wnt signaling [50,51].
The finding of a vertebrate-specific LGR-RSPO receptor ligand
system being uncoupled to heterotrimeric G proteins is rather
surprising, but perhaps not unexpected since they are the only
receptors of this family that are specifically associated with stem
cell function among the hundreds of 7TM rhodopsin-like
receptors. Delineation of the signaling mechanisms of LGR4–6
will provide important insights to the function of these receptors
and the control of proliferation and differentiation of adult stem
cells.
LGR4–6 are all known to be associated with various types of
cancer, but their roles and mechanisms in oncogenesis remain
largely unknown. LGR4 expression was shown to be increased in
approximately half of colon cancer cases with high levels being
associated with more severe metastasis [52]. For LGR5, earlier
studies suggest that it has increased expression in colon cancer and
basal cell carcinoma with expression potentially enriched in cancer
stem cells [53–55]. More recent publications, on the other hand,
reported that LGR5 may actually function as a tumor suppressor
and its expression level is inversely correlated with prognosis
[56,57]. Somatic cancer mutations of LGR5 have also been
Table 1. Somatic cancer mutations of LGR6 listed in the COSMIC database as of Jan-2012.
Cancer Mutation Affected Domain Zygosity Mutated/Total Cases (%)
Colon (adenocarcinoma) P928H C-terminal tail Homozygous 3/37 (8%)
G725C Extracellular loop 2 Heterozygous
S299insGRS ECD Heterozygous
Pancreas V746I TM5 Heterozygous 1/23 (4%)
Ovary (serous carcinoma) F230fs*6 ECD Heterozygous 2/3 (67%)
D536G ECD Heterozygous
doi:10.1371/journal.pone.0037137.t001
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exception of one truncation [21], supporting its role as a tumor
suppressor. For LGR6, the initial evidence came from the finding
of three mutations in random, total exon sequencing of 37 colon
cancer samples [17]. A transcriptome-wide approach showed that
LGR6 is hypermethylated in the promoter region in ,20% of
Figure 4. Functional and binding analyses of LGR6 mutants. A, TOPFlash assay of LGR6 mutants on RSPO1-induced potentiation of Wnt/b-
catenin signaling. HEK293T cells were transiently transfected with expression plasmids as indicated with a combination of super 86TOPFlash and
pRL-SV40 reporter gene constructs, and then stimulated with serial dilutions of purified recombinant RSPO1 in the presence of Wnt3a CM. All error
bars are SEM (n=4). B, Expression levels of LGR6 mutants and WT in HEK 293T cells in transient transfection paradigms. Total cell lysates were treated
with Laemmli buffer for 1 hr at 37uC, fractionated by SDS-PAGE using 4–20% gels, electrophoretically transferred to nitrocellulose membrane, and
then probed with anti-Flag antibody. The signal was detected by ECL Western blotting detection reagents (Amersham Biosciences). b-actin was also
probed as loading control. C, Time course of changes in Wnt3a-RSPO1-induced b-catenin accumulation and LRP6 phosphorylation in vector, LGR6-WT
and insGRS-overexpressing cells. HEK293 cells stably expressing vector, LGR6-WT or insGRS were stimulated with 1 ng/ml RSPO1 plus Wnt3a CM for
0–6 hrs. Total cell lysates were probed with antibodies against Flag-LGR6, phosphor-Ser1490, total LRP6, and b-actin. For the analysis of
nonmembrane-bound b-catenin, the cell lysates were cleared with ConA-sepharose beads and then probed with an antibody against b-catenin as
described before [9]. D, mRSPO1-Fc binding to LGR6-insGRS and WT. HEK293 cells stably expressing Flag-LGR6-WT or insGRS were incubated with
mRSPO1-Fc at 37uC for 1 hr. The cells were fixed, permeabilized, and then co-stained with anti-Flag (red) and anti-IgG2a (green) antibodies to detect
LGR6 and mRSPO1-Fc, respectively. Nuclei (blue) were counterstained with To-Pro-3.
doi:10.1371/journal.pone.0037137.g004
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in up to 50% of colon cancer samples depending patient ethnicity
[20]. Our analysis of the three mutations found in colon cancer
clearly indicates that one of them (insGRS) is a loss-of-function
mutation. Based on these data, it is suggested that LGR6 plays the
role of a tumor suppressor in colon and ovarian cancer.
Interestingly, RSPO1, a high affinity ligand of LGR6, also
appears to function as a tumor suppressor. Loss of RSPO1 in
females recessively leads to increased risk of squamous cell
carcinoma [58]. The notion that LGR6 is expressed specifically
in a population of stem cells that can give rise to all cell lineages of
the skin and that cancer often originates from stem cells suggests
that LGR6 may be the underlying receptor for the tumor
suppressive role of RSPO1. On the other hand, the finding that
LGR6 has positive effects on Wnt/b-catenin signaling and cell
migration appears to be inconsistent with a tumor suppressor
function. It is generally believed that hyperactivation of Wnt/b-
catenin signaling leads to increased cell proliferation and cell
migration is important for metastasis, both of which are expected
to have oncogenic function. However, emerging evidence suggests
that Wnt/b-catenin signaling has to be kept at an appropriate
(‘‘just right’’) level to balance proliferation, differentiation and
apoptosis [59,60]. Thus, suppression of LGR6 function may be
important for cancer cells to maintain the right level of Wnt/b-
catenin signaling. As for cell migration, the effect of LGR6 may be
specific to HeLa cells. LGR5, for example, showed oncogenic
properties in colon cancer cells and basal cell carcinoma cells
[53,54], but displayed tumor suppressor function in colon cancer
cell lines with b-catenin mutations [56]. Interestingly, the tumor
sample containing the LGR6 insGRS mutation also has mutation
in APC but not in b-catenin [21], suggesting that the action of
LGR6 does not depend on the genetic status of b-catenin.
Nevertheless, the finding of loss-of-function mutations in cancer
cells and promoter hypermethylation strongly argues that LGR6
functions as a tumor suppress in colon and ovarian cancer.
In summary, we characterized the binding and functional
activities of RSPO1–4 on LGR6 and found that LGR6 has the
highest affinity for RSPO2. Stimulation of LGR6 with RSPO1
leads to increased LRP6 phosphorylation and b-catenin-controlled
transcriptional activity. We also determined the activity of three
somatic mutations found in colon cancer and demonstrated that
the insGRS mutant is a loss-of-function mutation due to failure of
Figure 5. Expression profiling of LGR4–6 and RSPO1–4 and migration assay of HeLa cells overexpressing LGR6. A, Expression levels of
LGR4–6 in HEK293 cells and a panel of cancer cell lines determined by quantitative RT-PCR analysis. B, Expression levels of RPSO1–4 in HEK293 and a
panel of colon cancer cell lines determined by qPCR analysis. C, Cell migration analysis of HeLa cells stably expressing vector, LGR6-WT or insGRS after
treatments with vehicle control, RSPO1,Wnt3a-CM, or RSPO1+Wnt3a. Data are presented at mean 6 S.E.M. of three replicates after normalization to
vehicle control. The experiment was repeated once and both showed similar results. D & E, Expression analysis of LGR6-WT and insGRS in HeLa cells
by confocal immunofluorescence (D) and immunblotting (E) using an anti-Flag antibody.
doi:10.1371/journal.pone.0037137.g005
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increased cell migration in response to treatment with Wnt3a and
RSPO1. These results suggest that LGR6 is potentially a tumor
suppressor and provide a basis for future research into the roles
and mechanisms of LGR6 in oncogenesis.
Materials and Methods
DNA Constructs and Recombinant Proteins
A plasmid containing the full-length open reading frame (ORF)
of human LGR6 was purchased from Open Biosystems. The
sequence encoding a predicted mature form of human LGR6
(AA25–967, Genbank accession number NP_001017403) was
fused with a sequence encoding a Flag tag at the N terminus, and
then cloned downstream of a sequence encoding the CD8 signal
peptide (MALPVTALLLPLALLLHAA) in the vector pIRE-
Spuro3 (Clontech) using standard, PCR-based molecular cloning
procedures. LGR6 mutants were created from this wildtype (WT)
construct using the QuikChange site-directed mutagenesis kit
(Strategene, La Jolla, CA). The sequences of the primers used for
site-directed mutagenesis are listed in Table 2. The entire coding
regions of the mutant plasmids were bi-directionally sequenced to
verify that there were no errors introduced during PCR. All other
reagents and plasmids were as described previously [9].
Binding and functional analysis of LGR6 WT and mutants
Cell culture and transfection of HEK293 and HEK293T cells
(purchased from ATCC) were carried out as described previously
[9]. Binding of mRSPO1-Fc to cells expressing LGR6 at 4uC and
37uC were performed as before [9], except that Cy3-labeled anti-
Flag antibody was used. Measurements of cAMP levels, Ca
2+
mobilization, and b-arrestin translocation were carried out side-
by-side with LGR4 and LGR5 previously [9]. For the analysis of
the Ga(12/13) coupling pathway, HEK293T cells were transiently
transfected with 1 mg of SRF-RE-luc2P reporter plasmid (Pro-
mega) and 100 ng of pRL-SV40 plasmid together with 1 mgo f
LGR6-WT or vector control. Twenty four hours after transfection,
the cells were detached, seeded and serum starved overnight in a
384-well plate. Luciferase activity was measured after six hour
induction with serial dilutions of either RSPO1 or FBS using the
Dual-Glo
TM assay system (Promega) according to the manufac-
ture’s protocol.
Immunoblot Analysis
Immunoblotting of phosphorylated LRP6, total LRP6, and
cytosolic (nonmembrane bound) b-catenin were performed as
described previously [9]. Immunoblot analysis of Flag-LGR6 WT
and mutants were carried out using an anti-Flag (1:1000; Sigma)
using standard conditions.
Expression analysis of LGR4–6 in cancer cell lines and cell
migration assays
All cancer cell lines were grown in DMEM+10% FBS in a 37uC
incubator with 5% CO2 and 95% humidity. RNA isolation and
quantitative PCR analysis were carried out using primers and
conditions described previously [9]. The sequences of forward and
reverse primer used for LGR6 are 59-CTCTTCCCTTTC-
CTCTC-39 and 59- CTGAGTTTTGGTTGTATTTG-39, re-
spectively. For the generation of HeLa cells stably expressing
LGR6WT, mutant, or vector control, the corresponding plasmids
were transfected into HeLa cells with Fugene HD and selected
with puromycin (1 mg/ml). Drug-resistant cells from LGR6WT or
mutant transfected cells were sorted for receptor expression using a
Cy3-labeled anti-FLAG antibody. For cell migration assay, HeLa
cells stably expressing control vector, LGR6-WT or mutant were
studied in a permeable filter of transwell system (BD BioCoat
TM
Control 8.0 mm PET Membrane 24-well Cell culture inserts, BD
Biosciences). After trypsinization, cells was seeded at 1610
4 cells/
well into the upper chamber which contains culture medium with
1% FBS. Cell migration to the other side of membrane was
induced by 10% FBS-containing medium in the lower chamber
for 48 h at 37uC in a tissue culture incubator. Migrated cells in the
lower chamber were fixed in 4% PFA solution for 10 min, stained
in 0.03% crystal violet solution for 10 min, and then rinsed in
water. The stained cells were subjected to microscopic examina-
tion on a light microscope. Migrated cells were counted in ten
randomly selected fields per insert, and the values were averaged.
All experiments were performed at least twice with three replicates
under each migration condition.
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